Literature DB >> 12406892

Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors.

Fabrice Bovia1, Patrick Salmon, Thomas Matthes, Krisztian Kvell, Tuan H Nguyen, Christiane Werner-Favre, Marc Barnet, Monika Nagy, Florence Leuba, Jean-Francois Arrighi, Vincent Piguet, Didier Trono, Rudolf H Zubler.   

Abstract

We studied the transduction of primary human B lymphocytes and myeloma cells with lentiviral vectors. In peripheral blood B cells that had been activated with helper T cells (murine thymoma EL-4 B5) and cytokines, multiply attenuated HIV-1-derived vectors pseudotyped with vesicular stomatitis virus (VSV) G-envelope protein achieved the expression of green fluorescence protein (GFP) in 27% +/- 12% (mean +/- 1 SD; median, 27%) of B cells in different experiments. When compared in parallel cultures, the transducibility of B cells from different donors exhibited little variation. The human cytomegalovirus (CMV) promoter gave 4- to 6-fold higher GFP expression than did the human elongation factor-1alpha promoter. A murine retroviral vector pseudotyped with VSV G protein proved inefficient even in mitotically active primary B cells. B cells freshly stimulated with Epstein-Barr virus were also transducible by HIV vectors (24% +/- 9%), but B cells activated with CD40 ligand and cytokines resisted transduction. Thus, different culture systems gave different results. Freshly isolated, nondividing myeloma cells were efficiently transduced by HIV vectors; for 6 myelomas the range was 14% to 77% (median, 28%) GFP(+) cells. HIV vectors with a mutant integrase led to no significant GFP signal in primary B or myeloma cells, suggesting that vector integration was required for high transduction. In conclusion, HIV vectors are promising tools for studies of gene functions in primary human B cells and myeloma cells for the purposes of research and the development of gene therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406892     DOI: 10.1182/blood-2001-12-0249

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.

Authors:  Floriane Fusil; Sara Calattini; Fouzia Amirache; Jimmy Mancip; Caroline Costa; Justin B Robbins; Florian Douam; Dimitri Lavillette; Mansun Law; Thierry Defrance; Els Verhoeyen; François-Loïc Cosset
Journal:  Mol Ther       Date:  2015-08-18       Impact factor: 11.454

3.  Decreased expression of Kruppel-like factors in memory B cells induces the rapid response typical of secondary antibody responses.

Authors:  Kim L Good; Stuart G Tangye
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-02       Impact factor: 11.205

4.  Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio.

Authors:  Yong Chen; William M Miller; Ashok Aiyar
Journal:  Biotechnol Prog       Date:  2005 Jan-Feb

5.  Targeted cell entry of lentiviral vectors.

Authors:  Sabrina Funke; Andrea Maisner; Michael D Mühlebach; Ulrike Koehl; Manuel Grez; Roberto Cattaneo; Klaus Cichutek; Christian J Buchholz
Journal:  Mol Ther       Date:  2008-06-24       Impact factor: 11.454

6.  Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates.

Authors:  Olivier Menzel; Jacques Birraux; Barbara E Wildhaber; Caty Jond; Françoise Lasne; Walid Habre; Didier Trono; Tuan H Nguyen; Christophe Chardot
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

7.  Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells.

Authors:  Camille Lévy; Fouzia Amirache; Caroline Costa; Cecilia Frecha; Claude P Muller; Hasan Kweder; Robin Buckland; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

8.  Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses.

Authors:  D Ivacik; A Ely; N Ferry; P Arbuthnot
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

9.  Targeting lentiviral vectors to antigen-specific immunoglobulins.

Authors:  Leslie Ziegler; Lili Yang; Kye il Joo; Haiguang Yang; David Baltimore; Pin Wang
Journal:  Hum Gene Ther       Date:  2008-09       Impact factor: 5.695

10.  Lentivector-mediated RNAi efficiently downregulates expression of murine TNF-alpha gene in vitro and in vivo.

Authors:  Xuezhen Wang; Ronghua Tang; Zheng Xue; Feng Jiang; Min Zhang; Bitao Bu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.